½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1575361

¼¼°èÀÇ ¿îµ¿Àå¾Ö ½ÃÀå : À¯Çüº°, Ä¡·á¹ýº°, Åõ¿©°æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº° ¿¹Ãø(-2025-2030³â)

Dyskinesia Market by Type (Chorea, Levodopa-Induced Dyskinesia, Myoclonus), Treatment (Medications, Surgical Procedures, Therapies), Route of Administration, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿îµ¿Àå¾Ö´Â 2023³â 23¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 25¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.44%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 41¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿îµ¿Àå¾Ö´Â Á¾Á¾ ÆÄŲ½¼ º´°ú À¯»çÇÑ Áúº´°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ±ÙÀ°ÀÇ ºÒ¼öÀÇ, ºÒ±ÔÄ¢, ¸öÀÌ ¿òÁ÷ÀÌÁö ¾Ê´Â ¿òÁ÷ÀÓÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ ¹üÀ§´Â ÁÖ·Î ·¹º¸µµÆÄ¿Í °°Àº ¾à¹°ÀÇ Àå±â »ç¿ë°ú °ü·ÃµÈ ¾à¹° À¯¹ß ¿îµ¿Àå¾ÖÀ» Æ÷ÇÔÇÏ¿© ±¤¹üÀ§ÇÑ Áúº´¿¡ °ÉĨ´Ï´Ù. ¿îµ¿Àå¾Ö¿¡ ´ëóÇÒ Çʿ伺Àº ȯÀÚÀÇ QOL¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ ¹ß»ýÇϸç Á¶»ç¿Í Ä¡·á°¡ ÇʼöÀûÀÔ´Ï´Ù. Àû¿ë ¹üÀ§¿¡´Â ÁÖ·Î ½Å°æÀü´Þ ½Ã½ºÅÛÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ÀǾàÇ° ¹× Áõ»ó ¿ÏÈ­¸¦ Á¦°øÇÏ´Â Ä¡·á Àåºñ°¡ Æ÷ÇԵ˴ϴÙ. ÁÖ¿ä ÃÖÁ¾ ¿ëµµ ºÐ¾ß¿¡´Â º´¿ø, Ŭ¸®´Ð, ¿¬±¸ ±â°ü µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ½Å°æ ÁúȯÀÇ À¯º´·ü »ó½Â, ÀÎÁöµµ Çâ»ó, ÀÇ·á ±â¼úÀÇ Áøº¸ÀÔ´Ï´Ù. ±×·¯³ª, Ä¡·áºñÀÇ »ó½Â°ú ±âÁ¸ÀÇ Ä¡·á¹ý¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ëÀÌ ¼ºÀåÀÇ Å« °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× À¯ÀüÀÚ Ä¡·á Çõ½ÅÀº À¯¸ÁÇÑ ¹ßÀüÀÇ ±æÀ» Á¦°øÇÏ°í ½ÃÀå ¿ªÇп¡ Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÇöÀçÀÇ Ä¡·á ±âȸ´Â ºñµµÆĹμº Ä¡·á ¿É¼ÇÀÇ °³¹ß°ú ½Ç½Ã°£À¸·Î Áõ»óÀ» ÃßÀûÇϱâ À§ÇÑ ¿þ¾î·¯ºí ¸ð´ÏÅ͸µ ±â¼ú¿¡ ÀÖ½À´Ï´Ù. ±â¾÷µé¿¡°Ô´Â ÃÖ÷´Ü Ä¡·á¸¦ °³Ã´Çϱâ À§ÇØ ¿¬±¸ ±â°ü°ú Àû±ØÀûÀ¸·Î ÆÄÆ®³Ê½ÊÀ» ¸Î°í AI ÁÖµµ ¿¬±¸ Àü·«À» ½Ç½ÃÇÏ´Â °ÍÀÌ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» ÀÔÁõÇϱâ À§ÇØ Á¾ÇÕÀûÀÎ ÀÓ»ó½ÃÇè¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ Áß¿äÇÑ ±ÇÀå »çÇ×ÀÔ´Ï´Ù. ±ÔÁ¦ Àå¾Ö¹°°ú ¾ö°ÝÇÑ ½ÂÀÎ °úÁ¤°ú °°Àº ¹®Á¦´Â ½Å±Ô Ä¡·á¹ý ½ÃÀå ÁøÀÔÀ» Á¾Á¾ Áö¿¬½Ãŵ´Ï´Ù. °Ô´Ù°¡, Ä¡·á¿¡ ´ëÇÑ È¯ÀÚÀÇ ¹ÝÀÀÀÇ ºÒ±ÕÀϼºÀ¸·Î ÀÎÇØ, º¸´Ù °³º°È­µÈ Á¢±ÙÀÌ ÇÊ¿äÇÏ°í, Ç¥ÁØÈ­ ³ë·ÂÀÌ º¹ÀâÇØÁú ¼ö ÀÖ½À´Ï´Ù.Ä¡·á¹ýÀÇ Áö¸®Àû °ÝÂ÷´Â ½ÅÈï ½ÃÀå¿¡¼­ÀÇ º¸±ÞÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù. ±â¼ú Çõ½Å¿¡ ÃÖÀûÀÎ ºÐ¾ß·Î´Â ½Å°æº¸È£ Àü·«À̳ª ½Å°æÅðÇà¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹Ì»ý¹°°ú ÀåÀÇ »óÈ£ÀÛ¿ëÀÇ ÇØ¸í µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¿îµ¿Àå¾Ö ½ÃÀåÀº ƯÈ÷ »õ·Î¿î Çõ½ÅÀÌ ±âÁ¸ÀÇ ÇÑ°è¿¡ ´ëóÇÔÀ¸·Î½á ¼ºÀåÇϴ ż¼°¡ °®Ãß¾îÁ® ÀÖÁö¸¸, ÀáÀç´É·ÂÀ» ¿ÏÀüÈ÷ ¹ßÈÖÇϱâ À§Çؼ­´Â °íÀ¯ÀÇ º¹À⼺°ú °úÁ¦¸¦ Àü·«ÀûÀ¸·Î ±Øº¹ÇؾßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 23¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 25¾ï ´Þ·¯
¿¹Ãø³â(2030) 41¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 8.44%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿îµ¿Àå¾Ö ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¿îµ¿Àå¾Ö ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¦¾à±â¾÷°ú ¿¬±¸±â°üÀÇ Çù·Â°ü°è
    • ȯÀÚ Áß½ÉÀÇ Ä¡·á ¸ðµ¨ Áõ°¡¿¡ ÀÇÇÑ Ä¡·á ¾îµåÈ÷¾î·±½º¿Í Ä¡·á ¼ºÀûÀÇ Çâ»ó
    • ¿îµ¿Àå¾ÖÀÇ Ä¡·á¿¡¼­ ³·Àº ħ½À ¼ö¼ú ±â¼ú¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä
    • ¿îµ¿Àå¾ÖÀÇ ¿ÏÈ­¸¦ ¸ñÀûÀ¸·Î ÇÑ ½Å±Ô Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎ È®´ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÷´Ü Ä¡·á¿¡ µå´Â ´Ù¾×ÀÇ ºñ¿ë
  • ½ÃÀå ±âȸ
    • ¿îµ¿Àå¾Ö ȯÀÚÀÇ ¿îµ¿ ´É·Â°ú »îÀÇ ÁúÀ» ³ôÀÌ´Â Çõ½ÅÀûÀÎ Ä¡·á °³ÀÔ
    • ¿îµ¿Àå¾ÖÀÇ Á¶±â ¹ß°ß ¹× ÁøÇà ¸ð´ÏÅ͸µÀ» À§ÇÑ °í±Þ Áø´Ü µµ±¸ ¹× ±â¼ú
    • ¿îµ¿Àå¾Ö °ü¸®¸¦ À§ÇÑ ¾à¸®ÇÐÀû ¹× ºñ¾à¸®ÇÐÀû Á¢±ÙÀ» ÅëÇÕÇÑ °³ÀÎÈ­ Ä¡·á °èȹ
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç¿¡ µû¸¥ ºÎÀÛ¿ë

Portre's Five Forces: ¿îµ¿Àå¾Ö ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž±¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» È°¿ëÇÏ°í, ¾àÁ¡À» ÇØ°áÇÏ°í, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿îµ¿Àå¾Ö ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆľÇ

¿ÜºÎ °Å½Ãȯ°æ ¿äÀÎÀº ¿îµ¿Àå¾Ö ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿îµ¿Àå¾Ö ½ÃÀå °æÀï ±¸µµ ÆľÇ

¿îµ¿Àå¾Ö ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¿îµ¿Àå¾Ö ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿îµ¿Àå¾Ö ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : ¿îµ¿Àå¾Ö ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¿îµ¿Àå¾Ö ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D È°µ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇÏ°í ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Á¦¾à±â¾÷°ú ¿¬±¸±â°üÀÇ Á¦ÈÞ
      • Ä¡·áÀÇ Áؼö¿Í ¼º°ú¸¦ Çâ»ó½ÃÅ°´Â ȯÀÚ Áß½ÉÀÇ ÄÉ¾î ¸ðµ¨ Áõ°¡
      • Ä¡·á¸¦ À§ÇÑ ³·Àº ħ½À ¼ö¼ú ±â¼ú¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä ¿îµ¿Àå¾Ö
      • ¿îµ¿Àå¾ÖÀÇ ¿ÏÈ­¸¦ ¸ñÀûÀ¸·Î ÇÑ ½Å±Ô Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎ È®´ë
    • ¾ïÁ¦¿äÀÎ
      • °íµµÀÇ Ä¡·á¿¡ µå´Â °í¾×ÀÇ ºñ¿ë
    • ±âȸ
      • ¿îµ¿Àå¾Ö ȯÀÚÀÇ ¿îµ¿ ±â´É°ú »îÀÇ ÁúÀ» Çâ»ó½ÃÅ°´Â Çõ½ÅÀûÀÎ Ä¡·á °³ÀÔ
      • ¿îµ¿Àå¾ÖÀÇ ÁøÇàÀ» Á¶±â¿¡ °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇϱâ À§ÇÑ °í±Þ Áø´Ü µµ±¸ ¹× ±â¼ú
      • ¿îµ¿Àå¾Ö °ü¸®¸¦ À§ÇÑ ¾à¸®ÇÐÀû Á¢±Ù°ú ºñ¾à¸®ÇÐÀû Á¢±ÙÀ» ÅëÇÕÇÑ °³º° Ä¡·á °èȹ
    • °úÁ¦
      • ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú ¾àÀÇ ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »ç±³
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¿îµ¿Àå¾Ö ½ÃÀå : À¯Çüº°

  • ¹«µµº´
  • ·¹º¸µµÆÄ À¯¹ß¼º ¿îµ¿Àå¾Ö
  • °£´ë¼º±Ù°æ·ÃÁõ
  • ±¸°­ ¾È¸é ¿îµ¿ ÀÌ»ó
  • ¹ßÀÛ¼º ¿îµ¿ ÀÌ»ó
  • Áö¹ß¼º ¿îµ¿ ÀÌ»ó

Á¦7Àå ¿îµ¿Àå¾Ö ½ÃÀå : Ä¡·áº°

  • ÀǾàÇ°
    • Ç×Äݸ°Á¦
    • ±Û·çŸ¹Î»ê Â÷´ÜÁ¦
    • ¸ð³ë¾Æ¹Î ¼ö¼Û ¼ö½ÄÁ¦
  • ¼ö¼ú
    • ¾îºí·¹ÀÌ¼Ç ±â¼ú
    • ³ú½ÉºÎ Àڱؿä¹ý
  • Ä¡·á¹ý
    • ÀÛ¾÷¿ä¹ý
    • ¹°¸®Ä¡·á
    • ¾ð¾î¿ä¹ý

Á¦8Àå ¿îµ¿Àå¾Ö ½ÃÀå : Åõ¿© °æ·Îº°

  • ÁÖ»ç
  • ±¸°­
  • °æÇÇ ÆÐÄ¡

Á¦9Àå ¿îµ¿Àå¾Ö ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú¿¬±¸±â°ü
  • ȨÄɾî
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿îµ¿Àå¾Ö ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿îµ¿Àå¾Ö ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿, ¾ÆÇÁ¸®Ä«ÀÇ ¿îµ¿Àå¾Ö ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È
JHS 24.10.30

The Dyskinesia Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.50 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 4.13 billion by 2030.

Dyskinesia, often associated with Parkinson's disease and similar disorders, refers to involuntary, erratic, and writhing movements of muscles. Its scope covers a wide range of conditions, including drug-induced dyskinesia primarily linked to long-term use of medications like levodopa. The necessity for addressing dyskinesia arises from its significant impact on patients' quality of life, making research and treatment imperative. The application scope primarily includes pharmaceuticals targeting neurotransmitter systems and therapeutic devices offering symptom relief. Key end-use sectors include hospitals, clinics, and research institutions. Market growth is driven by rising prevalence of neurological disorders, increasing awareness, and advancements in medical technology. However, the high cost of treatment and side effects associated with existing therapies pose significant growth challenges. Innovations in personalized medicine and gene therapy offer promising avenues for development and could significantly impact market dynamics. Present opportunities lie within the development of non-dopaminergic treatment options and wearable monitoring technology for real-time symptom tracking. For businesses, actively engaging in partnerships with research institutions to pioneer cutting-edge treatments and implementing AI-driven research strategies could prove advantageous. A crucial recommendation is investing in comprehensive clinical trials to substantiate the efficacy and safety of new interventions. Challenges like regulatory hurdles and stringent approval processes often slow down market entry of novel therapies. Furthermore, the heterogeneity of patient responses to treatment necessitates more personalized approaches, which can complicate standardization efforts. Geographic disparities in treatment availability underscore the importance of expanding reach in emerging markets. The best areas for innovation include neuroprotective strategies and the exploration of microbiome-gut interactions affecting neurodegeneration. Overall, the dyskinesia market is poised for growth, particularly as new innovations address existing limitations, yet it requires strategic navigation of the inherent complexities and challenges to realize full potential.

KEY MARKET STATISTICS
Base Year [2023] USD 2.34 billion
Estimated Year [2024] USD 2.50 billion
Forecast Year [2030] USD 4.13 billion
CAGR (%) 8.44%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dyskinesia Market

The Dyskinesia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Collaborative efforts between pharmaceutical companies and research institutions
    • Increase in patient-centric care models enhancing treatment adherence and outcomes
    • High demand for minimally invasive surgical techniques for treating dyskinesia
    • Expanding pipeline of novel therapeutic agents aimed at mitigating dyskinesia symptoms
  • Market Restraints
    • High costs of advanced treatments
  • Market Opportunities
    • Innovative therapeutic interventions for enhancing mobility and quality of life in dyskinesia patients
    • Advanced diagnostic tools and technologies for early detection and monitoring of dyskinesia progression
    • Personalized treatment plans integrating pharmacological and non-pharmacological approaches for dyskinesia management
  • Market Challenges
    • Adverse medication effects along with stringent regulatory requirements

Porter's Five Forces: A Strategic Tool for Navigating the Dyskinesia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dyskinesia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dyskinesia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dyskinesia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dyskinesia Market

A detailed market share analysis in the Dyskinesia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dyskinesia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dyskinesia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dyskinesia Market

A strategic analysis of the Dyskinesia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dyskinesia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., BioArctic AB, GlaxoSmithKline plc, Intra-Cellular Therapies, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Lundbeck A/S, Medtronic plc, Merz Pharmaceuticals GmbH, Neurocrine Biosciences, Inc., Roche Holding AG, Sage Therapeutics, Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Ultragenyx Pharmaceutical Inc., and Voyager Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Dyskinesia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chorea, Levodopa-Induced Dyskinesia, Myoclonus, Orofacial Dyskinesia, Paroxysmal Dyskinesias, and Tardive Dyskinesia.
  • Based on Treatment, market is studied across Medications, Surgical Procedures, and Therapies. The Medications is further studied across Anticholinergics, Glutamate Blockers, and Monoamine Transport Modifiers. The Surgical Procedures is further studied across Ablative Techniques and Deep Brain Stimulation. The Therapies is further studied across Occupational Therapy, Physical Therapy, and Speech Therapy.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal Patches.
  • Based on End User, market is studied across Academic & Research Institutes, Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Collaborative efforts between pharmaceutical companies and research institutions
      • 5.1.1.2. Increase in patient-centric care models enhancing treatment adherence and outcomes
      • 5.1.1.3. High demand for minimally invasive surgical techniques for treating dyskinesia
      • 5.1.1.4. Expanding pipeline of novel therapeutic agents aimed at mitigating dyskinesia symptoms
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of advanced treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative therapeutic interventions for enhancing mobility and quality of life in dyskinesia patients
      • 5.1.3.2. Advanced diagnostic tools and technologies for early detection and monitoring of dyskinesia progression
      • 5.1.3.3. Personalized treatment plans integrating pharmacological and non-pharmacological approaches for dyskinesia management
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse medication effects along with stringent regulatory requirements
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dyskinesia Market, by Type

  • 6.1. Introduction
  • 6.2. Chorea
  • 6.3. Levodopa-Induced Dyskinesia
  • 6.4. Myoclonus
  • 6.5. Orofacial Dyskinesia
  • 6.6. Paroxysmal Dyskinesias
  • 6.7. Tardive Dyskinesia

7. Dyskinesia Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medications
    • 7.2.1. Anticholinergics
    • 7.2.2. Glutamate Blockers
    • 7.2.3. Monoamine Transport Modifiers
  • 7.3. Surgical Procedures
    • 7.3.1. Ablative Techniques
    • 7.3.2. Deep Brain Stimulation
  • 7.4. Therapies
    • 7.4.1. Occupational Therapy
    • 7.4.2. Physical Therapy
    • 7.4.3. Speech Therapy

8. Dyskinesia Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Transdermal Patches

9. Dyskinesia Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Homecare
  • 9.4. Hospitals
  • 9.5. Specialty Clinics

10. Americas Dyskinesia Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dyskinesia Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dyskinesia Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Acadia Pharmaceuticals Inc.
  • 3. Acorda Therapeutics, Inc.
  • 4. Adamas Pharmaceuticals, Inc.
  • 5. Amneal Pharmaceuticals, Inc.
  • 6. BioArctic AB
  • 7. GlaxoSmithKline plc
  • 8. Intra-Cellular Therapies, Inc.
  • 9. Ipsen Pharma
  • 10. Kyowa Kirin Co., Ltd.
  • 11. Lundbeck A/S
  • 12. Medtronic plc
  • 13. Merz Pharmaceuticals GmbH
  • 14. Neurocrine Biosciences, Inc.
  • 15. Roche Holding AG
  • 16. Sage Therapeutics, Inc.
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Ultragenyx Pharmaceutical Inc.
  • 20. Voyager Therapeutics, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦